Loading institutional data...
Loading institutional data...
Held by 407 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $26.57 today, the market must believe free cash flow compounds 6.1%/yr for a decade (off $261M normalized FCF).
The market's 6.1% is more conservative than its 6-yr track record.
2-stage DCF · 0.18B shares · net debt -$219M
mean 64.0% · volatility σ 78% · implied rate exceeded in 5/6 yrs
Central path = implied 6.1%/yr growth; shaded band = ±1σ (78%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $432M buybacks = $432M returned on $326M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 7 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 21%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 7 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $644.9M 100.0% | $570.4M 100.0% | $475.4M 100.0% | $419.1M 100.0% | $343.5M 100.0% | $206.9M 100.0% | $116.4M 100.0% |
| Cost of Revenue | $70.3M 10.9% | $55.9M 9.8% | $50.7M 10.7% | $53.5M 12.8% | $39.8M 11.6% | $31.2M 15.1% | $14.9M 12.8% |
| Gross Profit | $574.5M 89.1% | $514.5M 90.2% | $424.8M 89.3% | $365.6M 87.2% | $303.8M 88.4% | $175.7M 84.9% | $101.5M 87.2% |
| Research & Development | $130.7M 20.3% | $93.0M 16.3% | $82.0M 17.2% | $80.2M 19.1% | $62.4M 18.1% | $43.9M 21.2% | $32.4M 27.9% |
| Selling, General & Admin | $65.3M 10.1% | $45.7M 8.0% | $37.8M 8.0% | $36.7M 8.8% | $35.7M 10.4% | $16.5M 8.0% | $7.4M 6.4% |
| Total Operating Expenses | $359.6M 55.8% | $286.7M 50.3% | $260.9M 54.9% | $240.5M 57.4% | $190.2M 55.4% | $122.4M 59.2% | $79.3M 68.2% |
| Operating Income | $214.9M 33.3% | $227.8M 39.9% | $163.9M 34.5% | $125.1M 29.9% | $113.5M 33.0% | $53.3M 25.8% | $22.2M 19.0% |
| Other Income (Expense), net | $35.1M 5.4% | $35.8M 6.3% | $21.3M 4.5% | -$146K -0.0% | -$448K -0.1% | $4.5M 2.2% | $1.4M 1.2% |
| Pretax Income | $250.0M 38.8% | $263.6M 46.2% | $185.2M 39.0% | $133.2M 31.8% | $114.0M 33.2% | $57.8M 27.9% | $23.5M 20.2% |
| Income Tax Expense | $54.0M 8.4% | $40.4M 7.1% | $37.6M 7.9% | $20.3M 4.9% | -$40.8M -11.9% | $7.6M 3.7% | -$6.2M -5.3% |
| Net Income | $196.1M 30.4% | $223.2M 39.1% | $147.6M 31.0% | $112.8M 26.9% | $154.8M 45.1% | $50.2M 24.3% | $29.7M 25.5% |
| Per Share | |||||||
| EPS (Basic) | $1.05 | $1.19 | $0.78 | $0.58 | $0.82 | $0.29 | $0.16 |
| EPS (Diluted) | $0.98 | $1.11 | $0.72 | $0.53 | $0.70 | $0.23 | $0.13 |
| Weighted Avg Shares (Basic) | 187.0M | 186.8M | 190.2M | 193.2M | 163.5M | 74.3M | 66.8M |
| Weighted Avg Shares (Diluted) | 199.0M | 201.2M | 205.7M | 213.4M | 191.0M | 95.1M | 81.7M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| DOCS | $4.9B | 27.1× | 20.3× | 7.5× | 13.1% | 89.1% | 30.4% | 20.6% | 20.6% | — | 407 |
Peers = companies sharing DOCS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 5-yr range · 20th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 5-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
| Cost of Revenue | 12.8 | 15.1 | 11.6 | 12.8 | 10.7 | 9.8 | 10.9 |
| Gross Profit | 87.2 | 84.9 | 88.4 | 87.2 | 89.3 | 90.2 | 89.1 |
| R&D | 27.9 | 21.2 | 18.1 | 19.1 | 17.2 | 16.3 | 20.3 |
| SG&A | 6.4 | 8.0 | 10.4 | 8.8 | 8.0 | 8.0 | 10.1 |
| Operating Income | 19.0 | 25.8 | 33.0 | 29.9 | 34.5 | 39.9 | 33.3 |
| Income Tax | -5.3 | 3.7 | -11.9 | 4.9 | 7.9 | 7.1 | 8.4 |
| Net Income | 25.5 | 24.3 | 45.1 | 26.9 | 31.0 | 39.1 | 30.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on DOCS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.